SironRX Therapeutics, which spun out of Juventas Therapeutics and the Cleveland Clinic almost a year ago, is finding marked success in healing wounds. The company received $1 million in Third Frontier funding to continue clinical trials in wound healing.

“What we observed at Juventas in treatments for heart disease, we have observed in wound treatment with the same product,” explains Rahul Aras, SironRX president and CEO. “With SRX100, we accelerate treatment in dermal wounds and prevent scarring. While normal healing occurs in about 21 days, healing occurred 20 to 30 percent faster with significantly less scarring with our product.”

The product will be used in post-surgical incisions, chronic diabetic ulcers and burns. SironRX’s goal is to develop a cost-effective interactive wound therapy that can be topically administered with the potential to significantly improve function of the damaged tissue.

“It’s a great concept, applying concepts that make the body heal,” Aras says. “Repairing injured organs to heal themselves, I think that’s pretty exciting.”

As clinical trials continue, SironRX will be ramping up a full-time management teams, including a full-time CEO, and operational staff.

Source: Rahul Aras
Writer: Karin Connelly